Pharsight

Vimovo is owned by Horizon.

Vimovo contains Esomeprazole Magnesium; Naproxen.

Vimovo has a total of 9 drug patents out of which 6 drug patents have expired.

Expired drug patents of Vimovo are:

US8858996
US8852636
US9161920
US9198888
US9707181
US9345695

Vimovo was authorised for market use on 30 April, 2010.

Vimovo is available in tablet, delayed release;oral dosage forms.

Vimovo can be used as risk-reduction of nsaid-associated gastric ulcers in patients also taking low dose aspirin, risk-reduction of nsaid-associated gastric ulcer in patients requiring nsaid treatment, relief of signs and symptoms of arthritis and risk-reduction of nsaid-associated gastric ulcer, risk-reduction of nsaid gastric ulcer in patients requiring chronic nsaid treatment.

The generics of Vimovo are possible to be released after 17 October, 2031.

Application	Filing Date	Opposition Party	Legal Status
EP02734602A	2011-04-21	CHATFIELD PHARMACEUTICALS LIMITED	Patent maintained as amended
EP02734602A	2011-04-15	STRAWMAN LIMITED	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner
US9393208	July, 2018	Terminated-Other	Pozen Inc.	Dr. Reddy's Lab., Inc.
US9220698	April, 2018	FWD Entered	Horizon Pharma USA, Inc.	Dr. Reddy's Laboratories, Inc.
US9393208	December, 2017	FWD Entered	Horizon Pharma USA, Inc.	Mylan Pharmaceuticals Inc.
US9220698	August, 2017	Terminated-Other	Horizon Pharma USA, Inc.	Mylan Pharmaceuticals Inc.
US8858996	August, 2015	FWD Entered	Pozen Inc.	Lupin Pharmaceuticals Inc.
US8852636	August, 2015	Terminated-Denied	Pozen Inc.	Lupin Pharmaceuticals Inc
US8945621	August, 2015	FWD Entered	Pozen Inc	Coalition for Affordable Drugs VII LLC
US8852636	August, 2015	Terminated-Denied	Pozen Inc.	Coalition for Affordable Drugs VII LLC
US8858996	June, 2015	Terminated-Denied	Pozen Inc.	Coalition for Affordable Drugs VII LLC

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8858996	HORIZON	Pharmaceutical compositions for the coordinated delivery of NSAIDS	May, 2022 (9 months ago)
US8852636	HORIZON	Pharmaceutical compositions for the coordinated delivery of NSAIDs	May, 2022 (9 months ago)
US9161920	HORIZON	Pharmaceutical compositions for the coordinated delivery of NSAIDs	May, 2022 (9 months ago)
US9198888	HORIZON	Pharmaceutical compositions for the coordinated delivery of NSAIDs	May, 2022 (9 months ago)
US9707181	HORIZON	Pharmaceutical compositions for the coordinated delivery of NSAIDs	May, 2022 (9 months ago)
US9345695	HORIZON	Pharmaceutical compositions for the coordinated delivery of NSAIDs	May, 2022 (9 months ago)
US9393208	HORIZON	Method for delivering a pharmaceutical composition to patient in need thereof	Sep, 2029 (6 years from now)
US9220698	HORIZON	Method for delivering a pharmaceutical composition to patient in need thereof	Mar, 2031 (7 years from now)
US8945621	HORIZON	Method for treating a patient at risk for developing an NSAID-associated ulcer	Oct, 2031 (8 years from now)

Drugs and Companies using ESOMEPRAZOLE MAGNESIUM; NAPROXEN ingredient

Market Authorisation Date: 30 April, 2010

Treatment: Relief of signs and symptoms of arthritis and risk-reduction of nsaid-associated gastric ulcer; Risk-reduction of nsaid gastric ulcer in patients requiring chronic nsaid treatment; Risk-reduction of n...

Dosage: TABLET, DELAYED RELEASE;ORAL